Dominguez Castillo, Eduardo
Criner, Gerard J.
GroupCOVID-19 Research Group (Temple University)
DepartmentThoracic Medicine and Surgery
Hematology and Oncology
Permanent link to this recordhttp://hdl.handle.net/20.500.12613/4153
MetadataShow full item record
AbstractCoronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality because of a lack of effective therapies. Therapeutic strategies under investigation target the overactive cytokine response with anti-cytokine or immunomodulators therapies. We present a unique case of severe cytokine storm resistant to multiple anti-cytokine therapies, but eventually responsive to etoposide. Thus, etoposide may have a role as salvage therapy in treatment of cytokine storm in COVID-19. To our knowledge, this is the first reported case of use of etoposide in COVID-19.
Citation to related workElsevier
ADA complianceFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact firstname.lastname@example.org